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Abstract and Keywords
This article provides new estimates of systematic risk and the cost of equity capital for 
the pharmaceutical, biotechnology, and medical device sectors. The main analysis 
employs data for pharmaceutical, biotechnology, and medical device firms with publicly 
traded stock on US exchanges (including foreign-owned firms) with at least $100 million 
of market capitalization during the periods 2001–2005 and 2006–2008. Two frameworks 
are used for estimating firms' risk and the cost of equity capital: the capital asset pricing 
model (CAPM) and the empirically driven three risk-factor model of Fama and French (the 
F-F model). The article is organized as follows. The first section briefly reviews prior work 
and discusses the likely relation between the cost of equity capital and R&D intensity. The 
next section outlines the CAPM and F-F models and their empirical implementation. The 
data and samples are discussed in the third section. The fourth section presents beta and 
cost of equity capital estimates for equally weighted portfolios formed by sector and by 
sector and firm size. The fifth section presents results concerning the relationship 
between individual firm betas and R&D intensity, and it is followed by a final concluding 
section.
Keywords: systemic risk, equity capital cost, pharmaceutical industry, biotechnology industry, medical device 
industry, capital asset pricing model, risk-factor model
THE investment, financing, and risk management decisions of pharmaceutical, 
biotechnology, and medical device firms are fundamentally important to the development 
and availability of innovative treatments to enhance health outcomes and the quality of 
life. Economically efficient investment, including research and development (R&D), 
requires undertaking projects with positive net present value (i.e., projects for which the 
discounted value of expected net cash flows is positive, where the discount rate reflects 
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investors’ opportunity cost of capital). The cost of capital therefore has significant effects 
on investment decisions. It also affects the minimum product prices that are required to 
make basic research and particular R&D projects economically attractive.
Given long R&D cycles and relatively low scientific success rates for individual projects, 
the effects of the cost of capital on investment decisions can be particularly large for the 
pharmaceutical, biotechnology, and medical device sectors. Because firms in these 
sectors are primarily financed by equity (common equity issues and retained earnings), as 
opposed to debt, the relevant cost of capital for investment decisions is dominated by the 
cost of equity capital (see, e.g., Myers and Shyam-Sunder 1996). Estimates of the cost of 
equity capital and understanding of factors that influence the cost of equity are 
therefore highly relevant to project development and policy issues, including drug and 
device pricing and measurement of the average cost of developing a new drug or device 
(e.g., DiMasi et al. 2003; DiMasi and Grabowski 2007; Vernon et al. 2010).
This study provides new estimates of systematic risk and the cost of equity capital for the 
pharmaceutical, biotechnology, and medical device sectors. The main analysis employs 
data for pharmaceutical, biotechnology, and medical device firms with publicly traded 
stock on US exchanges (including foreign-owned firms) with at least $100 million of 
market capitalization during the periods 2001–2005 and 2006–2008. Two frameworks are 
used for estimating firms’ risk and the cost of equity capital: the capital asset pricing 
model (CAPM) and the empirically driven three risk-factor model of Fama and French (F-
F model) (Fama and French 1992, 1993).
The CAPM is widely used by corporations, investment banks, and portfolio managers in 
valuation and capital budgeting. It is based on the simple notion that investors who are 
able to diversify at low cost will demand compensation only for bearing nondiversifiable 
risk. The CAPM posits that the risk premium required by investors for holding a 
particular security will depend on the sensitivity of the security's return to returns on the 
market portfolio of risky assets, as measured by the security's “beta.” Beta is a measure 
of a security's market risk that cannot be diversified away by combining it with other 
securities in a portfolio.
The CAPM assumes a single market risk factor. The F-F model was developed in response 
to evidence that, controlling for market beta, historical mean returns on stocks for small 
firms were higher than for large firms and historical mean returns for stocks with high 
ratios of book-to-market equity (“value” stocks) were higher than for stocks with low 
book-to-market equity (“growth” or “glamour” stocks). The F-F model posits that two 
nondiversifiable risk factors affect the required return on a security in addition to its 
market risk: (1) a risk factor related to firms’ market capitalization (the size factor), and 
(2) a risk factor related to firms’ ratio of book value of equity capital to the market value 
of equity capital (the book-to-market factor). A firm's cost of equity capital depends on its 
market, size, and book-to-market betas and the risk premia associated with each risk 
factor. Although the F-F model is less widely used in valuation and capital budgeting than 
(p. 76) 
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the CAPM, it is often used in comparison with the CAPM. In addition, many investment 
analysts employ cost of equity capital estimates that incorporate a size factor if not both a 
size and a book-to-market factor.
This study's empirical analysis focuses on possible differences in risk and the associated 
cost of equity capital across the pharmaceutical, biotechnology, and device sectors and 
between large and small firms within each sector. It also provides evidence of the 
relationship between firms’ risk, cost of equity capital, and intensity of R&D 
expenditures, as measured by the ratio of R&D to total revenues (“sales”). Prior work 
(discussed later) has emphasized that whereas technical uncertainty associated with 
success or failure during product development and approval is likely diversifiable, 
expected future R&D expenditures for a given project create a form of leverage 
analogous to operating and financial leverage. That leverage, which declines as the 
project moves through development, increases the systematic risk that arises from 
correlation between the project's projected commercial value conditional on success and 
underlying risk factors priced by investors, such as market risk.
There are four principal findings from the empirical analysis. First, R&D intensity is 
positively related to market betas and thus to the estimated cost of equity capital, after 
controlling for firms’ principal sector of operations (pharmaceutical, biotechnology, or 
device). Second, the choice of model matters. The CAPM and F-F models can produce 
materially different estimates of the cost of equity capital. In particular, the results for the 
F-F model imply a size-related risk premium in the cost of equity capital for smaller firms 
in each sector. Third, after controlling for R&D intensity, average market betas can differ 
significantly across sectors. Biotech firms had significantly higher market betas than 
pharmaceutical firms during the period 2001–2005. Device firms had significantly higher 
betas than pharmaceutical firms during 2006–2008. Fourth, the time period matters, as 
implied by the results of this study and by a large negative and significant average book-
to-market beta value for large biotech firms during 2001–2005, which significantly 
lowered the estimated cost of capital during that period but did not persist during 2006–
2008.
These results were obtained from data for publicly-traded firms with at least $100 million 
of market capitalization at the beginning of the sample periods. The cost of equity capital 
is usually higher, on average, for smaller publicly-traded firms and privately held firms for 
at least two reasons (e.g., Cockburn and Lerner 2009). First, investors are likely to 
require a higher expected return for smaller or privately held firms as compensation for 
the lack of liquidity from investing in such firms (e.g., Cockburn and Lerner). Second, 
smaller and privately held firms usually have a single compound or a few compounds in 
early stages of development, which results in high R&D intensity and CAPM betas.
The first section that follows briefly reviews prior work and discusses the likely relation 
between the cost of equity capital and R&D intensity. The next section outlines the CAPM 
and F-F models and their empirical implementation. The data and samples are discussed 
in the third section. The fourth section presents beta and cost of equity capital estimates 
(p. 77) 
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for equally weighted portfolios formed by sector and by sector and firm size. The fifth 
section presents results concerning the relationship between individual firm betas and 
R&D intensity, and it is followed by a final concluding section.
Prior Work
Enormous theoretical and empirical literatures have considered the cost of capital in 
general and the cost of equity capital in particular. Much of this research addresses the 
CAPM and the F-F models, including their ability to explain cross-sectional stock 
returns (see, e.g., Fama and French 1992, 1993, 2006). Although much of this work castes 
doubt on its empirical veracity, the CAPM remains the most widely used method in 
practice for estimating the cost of capital.
The question of whether size and book-to-market factors in returns are persistent and are 
related to underlying priced risk factors has been extensively debated, including whether 
historical size-related return premia compensate for risk related to illiquidity or financial 
distress (see van Dijk 2010) and whether historical book-to-market–related return premia 
compensate for risk related to earnings volatility or financial distress.
Studies that have employed the CAPM or F-F model to estimate the cost of equity capital 
for pharmaceutical and biotechnology firms are summarized in Table 4.1.  The CAPM 
beta and cost of capital estimates are fairly stable across studies and time periods, with 
no obvious secular trend. The results suggest higher CAPM betas for biotechnology firms 
and smaller pharmaceutical firms and positive F-F size betas for the small biotechnology 
firms and pharmaceutical firms. The analysis in this chapter extends these studies by 
considering relatively large samples of biotechnology, pharmaceutical, and device firms; 
including the analysis of post-2005 data; and specifically considering the relationship 
between beta estimates, cost of capital, and R&D intensity at the firm level.
As summarized in Table 4.1, Grabowski and Vernon (1990) and DiMasi et al. 1991) 
utilized a real cost of capital estimate of 9 percent assuming an average CAPM beta of 1.0 
based on beta estimates using data from the 1970s to the mid-1980s. The US Congress’ 
Office of Technology Assessment (1993) reported an average pharmaceutical firm beta of 
0.90 based on annual estimates for 20 to 25 firms during the period 1975–1987. Myers 
and Shyam-Sunder (1996) provided CAPM-based cost of capital estimates for large 
pharmaceutical firms as of 1980, 1985, and 1990. They reported mean CAPM betas of 
0.98, 0.70, and 1.04 for the 1975–1979, 1981–1985, and 1985–1989 periods, respectively. 
They also reported an average beta of 1.54 using 1984–1988 data for seven small 
pharmaceutical and biotechnology firms.
Myers and Howe (1997) report an average CAPM beta of 1.05 for 13 large 
pharmaceutical firms using data for 1989–1993 and an average beta of 1.43 using annual 
data on weekly returns during 1986–1992 for 39 biotechnology firms with traded stock 
(p. 78) 
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throughout the period. DiMasi et al. (2003) used the Myers and Shyam-Sunder, Myers 
and Howe, and updated beta estimates to estimate the cost of capital and resulting 
opportunity costs for drugs in development.
Golec and Vernon (2007) used the F-F model to estimate cost of capital for samples of 
pharmaceutical and biotechnology firms using 1982–2005 data. The average market 
betas were 0.92 for pharmaceuticals and 1.06 for biotechnology 
firms. The F-F size betas were large and significant for both samples, especially for 
biotechs, increasing the estimated cost of capital. The book-to-market factor betas were 
close to zero and insignificant for both sectors. Vernon et al. (2010) compared cost of 
capital estimates obtained using the CAPM and F-F models for pharmaceutical firms with 
3 to 10 years of returns data ending in 1980 and 1986. The F-F cost of capital estimates 
were 300 to 600 basis points greater using the F-F model due to large estimated size 
betas.
(p. 79) (p. 80) (p. 81) 
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Table 4.1 Prior studies of pharmaceutical and biotechnology firms’ cost of capital
Study Model Sample Time Period Mean 
Market 
Beta
Nominal 
Cost of 
Equity 
(WACC)
Real Cost of 
Equity 
(WACC)
Notes
Grabowski & 
Vernon 
(1990) & 
DiMasi et al 
(1991)
CAPM Pharma 1970s to 
mid-1980s
1.0 9% Market beta 
used in cost 
of equity 
calculation
Office of 
Technology 
Assessment 
(1993)
CAPM 20–25 
Pharma 
firms
Annual, 
1975–1987
0.90 14.6% 
(14.0%)
6.8% Risk-free 
rate; 8.7% 
risk premium
Myers and 
Shyam-
Sunder (MS-
S) (1996)
CAPM 14 Pharma 
firms, 
market cap. 
at least 
$250m.
1975–1979 0.98 17.9% 
(17.2%)
10.3% (9.7%) Equally-
weighted 
industry 
portfolio; 
8.7% risk 
premium
1981–1985 0.70 16.7% 
(16.1%)
11.3% 
(10.8%)
1995–1989 1.04 15.9% 
(15.9%)
10.9% 
(10.3%)
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7 Small 
pharma & 
biotech firms
1984–1988 1.54 21.1% 
(19.1%)
16.1% 
(14.1%)
Myers & 
Howe (MH) 
(1997)
CAPM 13 Pharma 
firms
1989–1993 1.05 14.2% 
(13.7%)
11.2% 
(10.7%)
Equally-
weighted; 
8.7% risk 
premium
39 Biotechs 
traded since 
1986
Annual, 
1986–1992
1.43 Estimated by 
Shyam-
Sunder
DiMasi et al. 
(2003)
CAPM MS-S and 
MH; updated 
through 
2000
1985 0.98 16.1% 10.8%
1990 0.70 15.1% 10.6%
1994 1.04 14.2% 11.1%
2000 n.a. 15.0% 11.9%
Golec & 
Vernon 
(2007)
F-F Pharma 1982-2005 0.92 14.5% 0.8 size beta; 
0.02 B/M 
beta
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Biotech 1.06 16.2% 1.3 size beta; 
-0.10 B/M 
beta
Vernon et al. 
(2010)
CAPM Pharma 
firms, 3-10 
years of data
Ending 1980 11.0%
Ending 1986 10.4%
F-F Ending 1980 14.4% 0.66 size 
beta
Ending 1986 16.6% 0.99 size 
beta
Abbreviations: B/M, book-to-market; CAPM, capital asset pricing model; F-F, Fama and French model; n.a., not applicable; WACC, 
weighted average cost of capital.
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Myers and Shyam-Sunder (1996) explained why, given the implicit leverage associated 
with R&D, systematic risk will likely increase with R&D intensity and be greater for early-
stage projects compared with more mature projects. Myers and Howe (1997) provided a 
detailed explanation of how the quasi-fixed nature of planned R&D expenditures produces 
a form of leverage analogous to operating leverage associated with fixed operating costs 
and financial leverage associated with debt financing. They explained how variation in 
expected R&D over the lifetime of a project will cause R&D leverage and systematic risk 
to decline as a drug moves through the development process, giving rise to what they 
term the “risk-return staircase” in drug development.
Myers and Shyam-Sunder (1996) and Myers and Howe (1997) also observed that a 
positive relationship between R&D intensity and risk is implied by option pricing models. 
Berk et al. (2004) developed a dynamic model of multistage investment to illustrate how 
risk associated with ultimate cash flows in R&D–intensive ventures has a systematic 
component even though technical risk about advancement of a project is diversifiable. 
They viewed risky, R&D ventures as compound options with systematic uncertainty. They 
explained how an R&D–intensive project can be viewed as a series of compound options 
on the underlying cash flows of the project, with the strike price equivalent to the 
expected future investment in R&D. The risk premium on the project decreases if the 
project advances and, as a result, becomes more “in the money.” When a development 
stage is completed successfully, expected future investment drops, thus reducing the 
strike price and systematic risk of the project.
Myers and Shyam-Sunder (1996) conjectured that the higher mean beta they reported for 
small biotech and pharmaceutical companies compared with large pharmaceutical 
companies is consistent with an association between high R&D expenditures and high 
systematic risk. In an analysis of the potential effects of the Clinton administration's 
proposed Health Security Act of 1993 on pharmaceutical and biotechnology firms’ stock 
prices and R&D spending, Golec et al. (2005) used the CAPM to estimate abnormal stock 
returns and reported higher average CAPM betas (estimated with 1992–1993 data) for 
firms with higher average ratios of R&D to assets during 1989–1991.
The CAPM and Fama-French Models
The CAPM and F-F models are expected-return beta representations of linear factor 
pricing models.  The basic formulation of such a models is (1)
where E(R ) is the expected return on asset j, γ is the riskless rate of interest (or, if no 
riskless rate exists, the expected return on a zero-beta asset or portfolio), λ  (k = 1, 2, …, 
2 (p. 82) 
3
j
k
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K) is the expected risk premium for the kth risk factor, and β  (j = 1, 2, …, N; k = 1, 2, …, 
K) is the sensitivity of asset j's return to the kth risk factor.
The k underlying risk factors serve as a proxy for changes in the marginal utility of 
consumption and represent sources of risk that cannot be eliminated via portfolio 
diversification. Equation 1 portrays the fundamental principle that assets with greater 
risk sensitivities must provide investors with higher expected returns; that is, they tend to 
provide greater payoffs when consumption is high and the marginal utility of 
consumption is low, and smaller payoffs when consumption is low and the marginal utility 
of consumption is high.
The single risk factor in the CAPM is the return on the market portfolio of risky assets. 
With a riskless interest rate, R , each asset's expected return is (2)
where β  is the asset's market (“CAPM”) beta, E(R  – R ) is the expected excess return on 
the market portfolio (the “market risk premium”). E(R )  is the xpected required 
return (opportunity cost of equity capital) for stock j given its risk, β . If β  varies across 
assets in relation to some variable, x , the cost of capital will vary according to the 
following equation:
The F-F model posits three risk factors: (1) the excess return on the market 
portfolio, (2) the excess return on a portfolio of “small” stocks versus “big” stocks, and (3) 
the excess return on a portfolio of stocks with “high” ratios of book equity to market 
equity (book-to-market ratios) versus stocks with “low” book-to-market ratios. The 
expected return for asset j is (3)
where β  is the asset's excess market return beta (analogous to its CAPM beta), and
R , R , R , and R  are returns on the relevant portfolios of small, big, high book-to-
market, and low book-to-market stocks, respectively (see Fama and French 1993). If the 
F-F betas vary in relation to some variable, x , the cost of capital will likewise vary 
according to the following equation:
jk
F
j M F
j CAPM
j j
j
(p. 83) 
j,MKT-RF
S B H L
j
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Given equation 2, an estimate of a security's or a portfolio's CAPM beta can be obtained 
by using least squares to estimate the following model with returns data for a given 
period: (4)
Similarly, given equation 3, estimates of F-F betas can be obtained by estimating the 
following: (5)
Given beta estimates from equations 4 and 5, cost of equity capital estimates can be 
generated as a function of assumed values for the risk-free interest rate and market, size 
factor, and book-to-market factor risk premia. If, for example, the assumed risk-free rate 
is 5 percent and the assumed market, size factor, and book-to-market factor risk premia 
are 7 percent, 3 percent, and 4 percent, respectively, cost of equity capital estimates 
would be obtained as follows:
and
Assumed risk premia typically are based on historical mean excess returns for the 
relevant factor portfolios.
Data and Samples
This study focuses on estimates of CAPM and F-F betas using monthly returns data for 
two time periods: 2001–2005 (60 monthly returns) and 2006–2008 (36 monthly returns). 
The 2001–2005 period occurred after the technology stock (“dot.com”) boom and bust 
and predated the subprime mortgage and financial crisis that began in 2006 and 
accelerated during 2007–2008. The 2006–2008 period encompassed the crisis.
(p. 84) 
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The following criteria were used to select sample firms in each period:
• The firm's stock was included in the S&P Composite 1500 index and was identified in
Standard & Poor's Industry Survey at the end of the period for pharmaceutical firms, 
biotechnology firms, or medical device firms (health care products and supplies).
• Complete monthly returns were available from the Center for Research in Security 
Prices (CRSP) for the sample period.
• The firm was included in the Compustat database each year during the sample 
period and had nonmissing data for R&D expenses.
• The firm had market capitalization of $100 million or more at the beginning of the 
sample period.
These restrictions resulted in samples of 100 and 99 firms for 2001–2005 and 2006–2008, 
respectively. The firms were classified as primarily pharmaceutical, biotechnology, or medical 
device companies using the classification in Standard & Poor's Industry Survey.  Firms were 
then classified into large- and small-firm subgroups within each sector based on whether their 
market capitalization was above or below the median value for the entire sample at the 
beginning of the sample period ($2.51 billion for 2001–2005 and $2.48 billion for 2006–2008).
Monthly returns (including dividends) for each firm were obtained from the CRSP 
through Wharton Research Data Services (WRDS). Monthly returns in excess of the 
monthly Treasury bill yield (“excess returns”) were calculated for each security. The risk-
free rates were the monthly Treasury bill yields. Monthly excess returns on the value-
weighted portfolio of all securities traded on the NYSE, AMEX, and NASDAQ exchanges 
and on size-based and book-to-market ratio–based portfolios were obtained from 
WRDS (and are also available from Kenneth French's website).
R&D expense (net of acquired in-process R&D), total revenues (sales), and other financial 
data were obtained from the Compustat Annual Fundamentals files, also available 
through WRDS. The average lagged (one-year) ratio of a firm's annual R&D expense to its 
annual sales during the sample period was calculated as a measure of its average R&D 
intensity. A few values greater than 1 were truncated at 1 for each sample.  The average 
lagged ratio of a firm's long-term debt to value (long-term debt plus convertible debt plus 
preferred stock plus market value of equity) and the average lagged ratio of the firm's 
book value of equity to market value of equity also were calculated for each firm in each 
period.
Table 4.2 shows sample sizes, mean monthly excess returns, and mean and median values 
of market capitalization, R&D/sales, long-term debt/value, and book-to-market equity for 
each sector and sector-size subgroup for the 2001–2005 and 2006–2008 samples. 
Consistent with the general upward trend in stock prices, the mean excess returns were 
positive for each category during 2001–2005, with large excess returns for small 
pharmaceutical and small device firms. During the 2006–2008 period, as the overall 
market declined sharply in the latter half of 2008, the excess returns were negative for 
each group except small biotech and small device firms. Relatively few pharmaceutical 
firms had market capitalizations lower than the overall sample median value during each 
4
5
6
(p. 85) 
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period, whereas the device firm samples included many small firms. The giant 
pharmaceutical firms caused the mean values of market capitalization for the overall 
pharmaceutical and large pharmaceutical groups to be much greater than the medians.
During 2001–2005, the mean and median values of R&D/sales were much larger for 
biotechnology firms than for pharmaceutical and medical device firms. For example, the 
median of R&D/sales for the overall biotech group was 33 percent, compared with 10 
percent for pharmaceutical firms and 7 percent for device firms. During 2006–2008, 
however, the mean and median R&D/sales ratios for the large biotech group were much 
lower than in 2001–2005, and the difference in R&D intensity between large 
biotechnology firms and large firms in the other sectors narrowed considerably.
The mean and median values of book-to-market equity were roughly similar across groups 
and time periods. The mean and median values of long-term debt/value were low, just 
exceeding 10 percent for the small pharmaceutical group during 2006–2008. Because 
many firms in these sectors hold substantial cash and marketable securities, measures of 
net debt (total debt less cash and marketable securities) would be even lower (and 
negative for some firms). As a result of the minimal use of debt financing 
by most firms, the weighted-average cost of debt and equity capital will be approximately 
equal to the cost of equity capital.  For that reason, this paper, like a number of previous 
studies, focused on the cost of equity capital.
(p. 86) (p. 87) 
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Table 4.2 Means and medians (in brackets) of selected characteristics of sample firms
Pharmaceutical Biotechnology Device
Study 
Period
All Large Small All Large Small All Large Small
2001–
2005
Number 
of firms
31 22 9 26 17 9 44 12 32
Portfolio 
mean 
excess 
return
0.51% 0.13% 1.43% 0.31% 0.15% 0.61% 1.40% 0.60% 1.70%
Market 
equity 
($bill., 
12/31/00)
$40.2 
[$5.9]
$56.2 
[$10.2]
$1.0 
[$0.8]
$8.6 
[$3.3]
$12.6 
[$8.5]
$1.2 
[$1.1]
$4.6 
[$0.9]
$14.6 
[$8.0]
$0.8 
[$0.6]
R&D/
sales
0.179 
[0.104]
0.162 
[0.106]
0.221 
[0.086]
0.466 
[0.329]
0.511 
[0.327]
0.382 
[0.348]
0.090 
[0.072]
0.073 
[0.058]
0.097 
[0.077]*
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Long-
term 
debt/
value
0.074 
[0.041]
0.067 
[0.048]
0.092 
[0.041]
0.074 
[0.043]
0.082 
[0.064]
0.063 
[0.030]
0.069 
[0.034]
0.064 
[0.048]
0.071 
[0.032]
Book 
equity/
market 
equity
0.279 
[0.218]
0.306 
[0.230]
0.215 
[0.187]
0.280 
[0.286]
0.259 
[0.283]
0.318 
[0.328]
0.270 
[0.224]
0.264 
[0.182]
0.272 
[0.256]
2006–
2008
Number 
of firms
28 21 7 29 14 15 42 15 27
Portfolio 
mean 
excess 
return
–0.58% –0.66% –0.36% 0.36% –0.55% 0.42% –0.17% –0.51% 0.01%
Market 
equity 
($bill., 
12/31/05)
$40.8 
[$6.0]
$54.7 
[$37.9]
$1.2 
[$1.3]
$12.8 
[$2.6]
$24.5 
[$11.1]
$0.9 
[$0.9]
$4.2 
[$1.3]
$10.0 
[$6.9]
$0.9 
[$0.8]
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R&D/
sales
0.154 
[0.150]
0.153 
[0.152]
0.156 
[0.124]
0.307 
[0.194]
0.156 
[0.157]
0.447 
[0.321]
0.088 
[0.062]
0.082 
[0.062]
0.092 
[0.067]
Long-
term 
debt/
value
0.096 
[0.072]
0.088 
[0.071]
0.118 
[0.079]
0.082 
[0.056]
0.077 
[0.082]
0.087 
[0.047]
0.065 
[0.164]
0.063 
[0.055]
0.066 
[0.014]
Book 
equity/
market 
equity
0.308 
[0.295]
0.275 
[0.215]
0.405 
[0.356]
0.273 
[0.238]
0.290 
[0.264]
0.256 
[0.185]
0.294 
[0.259]
0.240 
[0.206]
0.324 
[0.264]
(*) Individual firm means were truncated at 1.
*
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Beta and Cost of Capital Estimates
Historical Market Betas for US Pharmaceutical Companies
To help place the study's results for the 2001–2005 and 2006–2008 samples in context 
and provide additional evidence on the historical pattern of pharmaceutical firms’ betas, 
Figure 4.1 first plots average CAPM beta estimates obtained with 60 months of data for 
sample periods ending each month from December 1969 through December 2008. These 
“rolling” beta estimates are shown for two samples. The first sample includes all US 
publicly-traded firms with Standard Industrial Classification (SIC) code 2834 
(Pharmaceutical Preparations). This sample includes generic as well as brand 
manufacturers and any biotechnology firms with that SIC code. It consists of 25 to 30 
companies during 1965–1980 and grows to about 50 companies in 1980, 130 companies 
in 2005, and 180 companies in 2008. The second sample includes seven large companies 
with SIC code 2834 that had publicly-traded stock throughout the period 1965–2008: 
Abbott Labs, Baxter, Bristol Myers (Squibb), Merck, Pfizer, Schering Plough, and Wyeth 
(American Home). It also includes Forest Labs from December 1967 onward and Eli Lilly 
from September 1970 onward.
The average CAPM beta 
estimates shown in Figure 
4.1 exhibit considerable 
volatility over time. The 
average betas are larger 
for the sample of all 
pharmaceutical firms than 
for the large 
pharmaceutical firms. The 
difference between the 
samples increased in 
conjunction with the large 
increase in the number of 
relatively small, publicly-
traded pharmaceutical 
firms during the past 
decade (most of which 
were smaller than the size cutoff for inclusion in the 2001–2006 and 2005–2008 samples). 
The average betas decline substantially for sample periods that included the technology 
stock bubble and its aftermath during the late 1990s and early 2000s, especially for the 
large-firm sample. The average betas also declined during late 2007 and 2008 as 
Click to view larger
Figure 4.1  Sixty-month rolling market betas for 
large US pharmaceutical companies and all 
publicly traded firms with Standard Industrial 
Classification (SIC) code 2834 (Pharmaceutical 
Preparations): December 1969 through 
December 2008.
(p. 88) 
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pharmaceutical stocks performed relatively well during the run-up to and onset of the 
2008 financial crisis.
CAPM Betas
Table 4.3 shows the results of using equation 4 to estimate CAPM betas for nine equally-
weighted portfolios: three sector portfolios and six sector-size portfolios. Beta estimates 
for equally-weighted portfolios are mathematically equivalent to the arithmetic mean of 
beta estimates for the securities in the portfolio. A multivariate regression model (MVRM) 
was used to jointly estimate the equations for the three sectors and for the six sector-size 
portfolios. The MVRM produces estimates identical to estimating the model for each 
portfolio separately, but it permits tests of equality of betas across portfolios that reflect 
possible correlations in disturbances across the portfolios.
For the 2001–2005 sample, the CAPM beta estimate was much larger for biotechs (1.32) 
than for the pharmaceutical firms (0.69) and the device firms (0.66), and the differences 
were statistically significant at the 0.01 level. During 2006–2008, the CAPM beta estimate 
for the pharmaceutical portfolio was 0.61. The large biotech beta dropped to 0.75, and 
the overall biotech beta dropped to 0.97. The beta estimate for the overall device 
portfolio was 0.89. The biotech and device betas for 2006–2008 were significantly greater 
than the pharmaceutical beta at the 0.05 level but not significantly 
different from each other. The coefficient of determination (R ) for the small 
pharmaceutical portfolio for 2006–2008, which included only 7 firms, was only 14 
percent. With the exception of the small pharmaceutical portfolio, the R  values were 
materially larger during 2006–2008 than during 2001–2005, especially for device firms.
(p. 89) (p. 90) 
2
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Table 4.3 CAPM model parameter estimates for equal-weighted sector/size-based portfolios using monthly returns
2001–2005 2006–2008
Group R-sq. R-sq.
Pharmaceutical 0.004 (0.406) 0.692 (0.000) 39.6% –0.000 (0.952) 0.611 (0.000) 52.0%
 Large 0.000 (0.080) 0.650 (0.000) 41.7% –0.001 (0.862) 0.641 (0.000) 59.3%
 Small 0.132 (0.100) 0.795 (0.000) 25.3% 0.001 (0.916) 0.521 (0.024) 14.2%
Biotechnology 0.001 (0.867) 1.319 (0.000) 46.2% 0.008 (0.217) 0.971 (0.000) 58.6%
 Large –0.000 (0.987) 1.302 (0.000) 41.8% 0.001 (0.807) 0.752 (0.000) 56.3%
 Small 0.004 (0.638) 1.350 (0.000) 42.6% 0.015 (0.132) 1.175 (0.000) 49.5%
Device 0.013 (0.001) 0.662 (0.000) 52.2% 0.006 (0.152) 0.889 (0.000) 73.7%
 Large 0.005 (0.230) 0.606 (0.000) 40.3% 0.002 (0.585) 0.836 (0.000) 69.4%
 Small 0.016 (0.001) 0.693 (0.000) 42.5% 0.008 (0.100) 0.919 (0.000) 69.0%
*
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(*) The regression equation is . Subsamples include firms in the sector with 
market value of equity above (Large) or below (Small) the median value for all sample firms at the beginning of the sample period. 
Two-tailed p values are shown in parentheses. Bold values are significant at the 0.05 level.
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The much higher biotech beta for 2001–2005 is consistent with the much higher R&D 
intensity for biotechs during this time period (see Table 4.2). The drop in biotech portfolio 
betas for 2006–2008 coincided with reductions in R&D intensity during this period 
compared with 2001–2005. The increases in the device portfolio betas during the 2006–
2008 period compared with 2001–2005 were not accompanied by any increase in R&D 
intensity.
The estimated “alphas” (intercepts) shown in Table 4.3 were generally positive, especially 
for the 2001–2005 period.  The values for the portfolio of small device firms were large 
and statistically significant, producing a large and significant estimate for the overall 
device portfolio as well. Therefore, controlling for beta, small device firms 
“outperformed” the overall stock market during this period. The estimated average risk-
adjusted excess return for the small device firm portfolio was 1.6 percent per month.
Fama-French Betas
Table 4.4 shows F-F betas obtained from estimating equation 5 for the nine portfolios. The 
market betas were generally lower than those shown in Table 4.3, with the exception of 
the overall and large pharmaceutical betas for 2001–2005, which were larger than the 
CAPM beta estimates. The market betas for biotechnology firms again were significantly 
larger than those for pharmaceutical and device firms during 2001–2005, and those for 
biotechs and device firms were larger than for pharmaceutical firms during 2006–2008. 
The estimated alphas for device firms during 2001–2005 were again large and significant 
due to the small device firm portfolio.
The inclusion of the size and book-to-market factors in the returns equation produced 
relatively little increase in R  compared with the CAPM model. However, consistent with 
Golec and Vernon (2007) and Vernon et al. (2010), the size-factor beta estimates were 
positive and statistically significant for the small-firm portfolios for each sector and time 
period, and in some cases this caused the size-factor beta to be positive and significant 
for the overall sector portfolio. Therefore, smaller pharmaceutical, biotech, and device 
stock returns were correlated with those of other small firms during these time periods. 
The large pharmaceutical firm portfolio had a negative and statistically significant size 
beta during 2001–2005.
The book-to-market betas were negative, large in absolute value, and 
significantly different from zero for the overall and large biotech portfolios during 2001–
2005. This result suggests that, after controlling for overall market returns, biotech stock 
returns tracked those of growth stocks during this time period, when average biotech 
R&D intensity was high. However, the statistically significant and negative book-to-
market betas for biotechs did not persist in 2006–2008, when the larger biotechs had 
matured with greater sales and lower R&D intensity.
9
2
(p. 91) (p. 92) 
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Table 4.4 Fama-French model parameter estimates for equal-weighted sector/size-based portfolios
2001–2005 2006–2008
Group R-sq. R-sq.
Pharmac
eutical
0.005 
(0.377)
0.724 
(0.000)
–0.115 
(0.520)
0.022 
(0.907)
40.1% –0.000 
(0.928)
0.583 
(0.000)
0.236 
(0.315)
–0.172 
(0.315)
53.9%
 Large 0.003 
(0.579)
0.771 
(0.000)
–0.440 
(0.020)
0.085 
(0.660)
39.7% –0.001 
(0.869)
0.643 
(0.000)
–0.009 
(0.966)
–0.001 
(0.966)
59.3%
 Small 0.009 
(0.279)
0.608 
(0.004)
0.679 
(0.015)
–0.132 
(0.641)
33.4% 0.000 
(0.963)
0.404 
(0.078)
0.970 
(0.050)
–0.692 
(0.166)
26.4%
Biotechn
ology
0.005 
(0.588)
1.068 
(0.000)
0.215 
(0.452)
–0.620 
(0.041)
50.8% 0.007 
(0.254)
0.869 
(0.000)
0.684 
(0.031)
–0.051 
(0.872)
64.3%
 Large 0.006 
(0.492)
1.043 
(0.000)
–0.020 
(0.949)
–0.795 
(0.015)
47.6% 0.001 
(0.860)
0.721 
(0.000)
0.185 
(0.486)
0.067 
(0.804)
57.2%
 Small 0.002 
(0.872)
1.115 
(0.000)
0.660 
(0.039)
–0.290 
(0.376)
47.9% 0.013 
(0.147)
1.008 
(0.000)
1.149 
(0.012)
–0.161 
(0.718)
58.7%
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Device 0.009 
(0.023)
0.639 
(0.000)
0.387 
(0.002)
0.178 
(0.163)
60.3% 0.005 
(0.156)
0.781 
(0.000)
0.614 
(0.001)
0.338 
(0.056)
84.1%
 Large 0.005 
(0.300)
0.685 
(0.000)
–0.125 
(0.416)
0.158 
(0.320)
42.2% 0.002 
(0.691)
0.788 
(0.000)
0.196 
(0.347)
0.418 
(0.056)
73.4%
 Small 0.010 
(0.029)
0.622 
(0.000)
0.579 
(0.000)
0.185 
(0.230)
55.4% 0.007 
(0.078)
0.778 
(0.000)
0.847 
(0.000)
0.293 
(0.124)
83.4%
Note: The regression equation is . Subsamples include firms 
in the sector with market value of equity above (Large) or below (Small) the median value for all sample firms at the beginning of the 
sample period. Two-tailed p values are shown in parentheses. Bold values are significant at the 0.05 level.
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Cost of Equity Capital Estimates
In Table 4.5, the CAPM and F-F beta estimates from Tables 4.3 and 4.4 and their 
estimated variances and covariances were used to generate (nominal) cost of equity 
capital estimates and 95 percent confidence intervals for those estimates. The estimates 
assume a risk-free rate of 5 percent per year, which corresponds to an expected annual 
real return on short-term Treasury bills of 2 percent plus an expected inflation rate of 3 
percent.  Cost of equity capital estimates for a different riskless rate could be obtained 
by simple addition or subtraction from those shown. The assumed market risk premium 
wasis 7 percent, which is approximately equal to the average annualized monthly excess 
market return available from CRSP during July 1926–June 2009 (7.1 percent). The 
expected excess return on small versus large stocks is assumed to be 3 percent, 
compared with an average annualized excess return on the F-F size portfolio of 2.8 
percent during that period. The expected excess return on high book-to-market versus 
low book-to-market stocks was assumed to be 4 percent. This is 1 percent (100 basis 
points) lower than the average annualized excess return on the F-F book-to-market factor 
portfolio from July 1926 to June 2009, but it is more in line with the average return on 
that portfolio since the mid-1980s.
Given these assumptions, the point estimates of the (nominal) cost of equity capital based 
on the 2001–2005 CAPM betas were approximately 10 percent for pharmaceutical and 
device firms and 14 percent for the more R&D–intensive and higher-beta biotechnology 
firms. For 2006–2008, the CAPM-based cost of equity capital estimates were 
approximately 9 percent for pharmaceuticals, 11 percent for device firms, and 12 percent 
for biotechs. For biotechs during 2006–2008, the estimated cost of equity was 13 percent 
for the higher-beta and more R&D–intensive small firms compared with 10 percent for 
larger biotechs.
For the F-F model, the estimated cost of equity capital values for pharmaceutical firms 
were similar to those obtained from the CAPM in both time periods. During 2001–2005, 
the lower F-F market beta for small pharmaceutical firms compared with the CAPM 
basically offsets the effects of the positive size beta for small firms; likewise, the 
higher F-F market beta for large pharmacetical firms offsets the negative size beta for 
large firms (see Table 4.4). A similar offset affects the estimated cost of equity for small 
pharmaceutical firms for 2006–2008. Due primarily to the positive size betas for small 
device firms, the F-F cost of equity values for device firms were about 1 to 2 percent 
higher than those obtained with the CAPM for 2001–2006 and 2 to 3 percent higher for 
2006–2008 (in part because of positive albeit insignificant book-to-market betas).
10
(p. 93) 
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Table 4.5 Illustrative cost of capital estimates by sector and group
2001–2005 2006–2008
Model Sector Group
CAPM Pharmaceu
tical
All 9.8% 8.3% 11.4% 9.3% 7.8% 10.7%
Large 9.6% 7.8% 11.3% 9.5% 8.2% 10.8%
Small 10.6% 8.1% 13.1% 8.6% 5.5% 11.8%
Biotechnol
ogy
All 14.2% 11.6% 16.9% 11.8% 9.8% 13.7%
Large 14.1% 11.3% 16.9% 10.2% 8.6% 11.9%
Small 14.5% 11.6% 17.3% 13.2% 10.3% 16.1%
Device All 9.6% 8.5% 10.8% 11.2% 9.9% 12.5%
Large 9.2% 7.9% 10.6% 10.9% 9.5% 12.2%
Small 9.8% 8.3% 11.2% 11.4% 9.9% 12.9%
*
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F-F Pharmaceu
tical
All 9.8% 6.9% 12.7% 9.1% 6.7% 11.5%
Large 9.4% 6.4% 12.4% 9.5% 7.3% 11.6%
Small 10.8% 6.3% 15.2% 8.0% 3.1% 12.8%
Biotechnol
ogy
All 10.6% 6.0% 15.3% 12.9% 9.8% 16.0%
Large 9.1% 4.0% 14.1% 10.9% 8.2% 13.6%
Small 13.6% 8.5% 18.8% 14.9% 10.5% 19.2%
Device All 11.3% 9.4% 13.3% 13.7% 12.0% 15.4%
Large 10.1% 7.6% 12.6% 12.8% 10.7% 14.9%
Small 11.8% 9.4% 14.2% 14.2% 12.3% 16.0%
Abbreviations: CAPM, capital asset pricing model; F-F, Fama and French model.
(*) The estimated costs of capital for the CAPM and FF models are  and 
. The statistics  and  represent the 95% confidence interval for .
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Given the large and negative book-to-market betas for large biotechs during 2001–2005, 
the estimated cost of equity for large biotechs using the F-F model during that period was 
much lower (9.1 percent) than the value obtained using the CAPM (14.1 percent). 
However, the disappearance of the relationship between biotechnology firm returns and 
book-to-market factor returns during 2006–2008 caused the cost of equity capital 
estimates for large biotechs to converge for the two models (10.9 percent for the F-F 
model and 10.2 percent for the CAPM).
Individual Firm Betas and R&D Intensity
Individual firm CAPM and F-F beta estimates were also obtained using equations 2 and 3 
for the 2001–2005 and 2006–2008 samples. In order to provide evidence of the 
relationship between beta estimates, sector, R&D intensity, and firm size (market 
capitalization), the following cross-sectional regression model was estimated for each 
beta estimate and period: (6)
where l = CAPM, MKT-RF (the difference between the expected return of the market and 
a risk-free asset), SML (the difference in the expected return of small and large stocks), 
or HML (the difference in the expected return of high book-to-market stocks and low 
book-to-market stocks); Biotech and Device are sector indicators; R&D/Sales is the firm's 
average ratio of R&D expense to sales for the period (again truncated at 1); and Log 
Market Equity is the log of the firm's market value of equity at the beginning of the 
sample period. Similar results to those reported here were obtained when indicators were 
included for generic pharmaceutical firms, for foreign-owned (or American Depository 
Receipt [ADR]) firms, and when the average ratio of long-term debt to value was 
included. None of the additional variables was significantly related to the estimated 
betas. Results with similar implications also were obtained by estimating models (without 
sector indicators) separately for each sector.
Table 4.6 shows bivariate correlations between the beta estimates, R&D intensity, log 
market equity, and long-term debt/value. As expected, R&D intensity was positively and 
significantly related to both CAPM and F-F market betas each period. It was negatively 
and significantly related to F-F book-to-market betas in 2001–2005. Again as expected, 
log market equity was negatively and significantly related to the F-F size betas.
Table 4.7 shows least squares estimates of equation 6 for each beta estimate and time 
period (with heteroskedasticity robust standard errors in parentheses). For the CAPM 
and F-F market betas, the estimates for the biotechnology and device indicators are 
(p. 94) 
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consistent with the findings of the portfolio analysis, except that the coefficient for 
the biotech indicator was not statistically significant during 2006–2008. The CAPM and F-
F market betas were positively and significantly related to R&D intensity in both periods. 
The coefficient on R&D intensity was 1.17 for the CAPM beta and 0.83 for the F-F market 
beta for 2001–2005. The coefficients were approximately 1 for both market beta 
measures for 2006–2008. Given an expected market risk premium of 7 percent, a 
coefficient for R&D intensity of 1 implies that, other factors being held constant, the cost 
of equity capital would increase 0.7 percent (70 basis points) for every increase of 10 
percentage points in R&D intensity.
(p. 95) 
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Table 4.6 Bivariate correlations: betas, R&D/sales, log market equity, and long-term debt/value
Period Indicator R&D/Sales Log 
Market 
Equity
Long-
Term 
Debt/
Value
2001–2005 1.00
0.89 1.00
0.21 0.00 1.00
–0.43 -0.06 0.11 1.00
R&D/Sales 0.63 0.47 0.01 -0.53 1.00
Log Market
Equity
-0.11 0.07 –0.70 -0.04 0.00 1.00
Long-Term 
Debt/Value
0.09 0.15 0.20 0.22 0.03 -0.04 1.00
*
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2006–2008 1.00
0.96 1.00
0.10 -0.17 1.00
0.01 -0.05 -0.04 1.00
R&D/Sales 0.41 0.36 0.19 -0.16 1.00
Log Market
Equity
-0.30 -0.18 -0.44 0.06 -0.15 1.00
Long-Term 
Debt/Value
0.04 0.04 -0.03 0.19 -0.03 -0.07 1.00
(*) Bold values are significant at the 0.05 level for two-tailed test.
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The F-F size betas were negatively and significantly related to log market equity for each 
period, with estimated coefficients of −0.31 and −0.22 for 2001–2005 and 2006–2008, 
respectively. Using a 3 percent size factor premium and the −0.22 estimate, an increase 
in market capitalization at the beginning of 2006 from $948 million 
(approximately the 25th percentile value for the 2006–2008 sample) to $16.2 billion 
(approximately the 75th percentile) would increase the estimated cost of equity by 1.9 
percent (190 basis points).
(p. 96) (p. 97) 
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Table 4.7 Cross-sectional determinants of CAPM and F-F beta estimates
2001–2005 (100 co.) 2006–2008 (99 co.)
Risk Measure Variable Coef. p-value Coef. p-value
Biotechnology 0.282 0.041 0.145 0.258
Device -0.002 0.986 0.272 0.015
R&D/Sales 1.173 0.000 1.052 0.025
Log Market Equity -0.045 0.072 -0.043 0.128
Constant 1.187 0.006 0.822 0.006
Adj. R 0.434 0.263
Biotechnology 0.136 0.344 0.120 0.397
Device 0.022 0.882 0.239 0.044
R&D/Sales 0.827 0.000 0.982 0.036
2
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Log Market Equity 0.019 0.503 -0.013 0.659
Constant 0.274 0.585 0.556 0.083
Adj. R 0.237 0.176
Biotechnology 0.193 0.211 0.092 0.694
Device -0.032 0.829 0.026 0.909
R&D/Sales -0.157 0.478 0.535 0.240
Log Market Equity -0.305 0.000 -0.222 0.000
Constant 4.715 0.000 2.223 0.000
Adj. R 0.504 0.212
Biotechnology -0.318 0.114 0.267 0.257
Device 0.051 0.770 0.646 0.013
R&D/Sales -1.144 0.000 -0.246 0.568
Log Market Equity -0.002 0.961 0.087 0.114
2
2
Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms
Page 34 of 40
PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). (c) Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an 
individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy).
Subscriber: University of Pennsylvania; date: 20 July 2017
Constant 0.254 0.680 -0.945 0.128
Adj. R 0.306 0.107
Abbreviations: Adj. R , adjusted coefficient of determination; CAPM, capital asset pricing model; F-F, Fama and French model.
Note: Bold values are significant at the 0.05 level for a two-tailed test with robust standard errors.
2
2
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Consistent with the portfolio results, there was a strong, negative relationship between F-
F book-to-market betas and R&D intensity during 2001–2005, but the estimated 
coefficient for R&D intensity was much closer to zero and insignificant for the 2006–2008 
sample. The coefficient for the device indicator in the book-to-market beta equation was 
positive and significant for 2006–2008. Other factors held constant, the magnitude of the 
coefficient, along with a 4 percent book-to-market factor risk premium, would imply a 2.5 
percent (250 basis) point higher cost of equity for device firms than for pharmaceutical 
firms. The explanation of this result (assuming that it is not spurious) is not clear.  It 
reflects in part the negative (albeit statistically insignificant) estimated beta for 
pharmaceutical firms during 2006–2008 (see Table 4.4).
Conclusions
This study provides estimates of systematic risk and the cost of equity capital for the 
pharmaceutical, biotechnology, and medical device sectors using data for firms with 
publicly traded stock on US exchanges (including foreign owned-firms) and market 
capitalization of at least $100 million during 2001–2005 and 2006–2008 using the CAPM 
model and F-F three-factor model. It also provides evidence of the relationship between 
firms’ systematic risk, cost of equity, and intensity of R&D expenditures.
There are four principal findings. First, R&D intensity, as measured by the ratio of R&D 
expense to sales, is positively related to market betas and thus to the estimated cost of 
equity capital, after controlling for firms’ principal sector of operations (pharmaceutical, 
biotechnology, or device). Second, the choice of model matters. The CAPM and F-F 
models can produce materially different estimates of the cost of equity capital. In 
particular, and consistent with other work, the F-F model results imply a size-related risk 
premium in the cost of equity for small firms in each sector. Third, after controlling for 
R&D intensity, average market betas can differ significantly across sectors. Biotech firms 
had significantly higher market betas than pharmaceutical firms during 2001–2005, and 
device firms had significantly higher betas than pharmaceutical firms during 2006–2008. 
Fourth, the time period matters, as implied by the preceding results and by the large 
negative and significant book-to-market beta for large biotech firms during 2001–
2005, which significantly lowered the estimated cost of capital during that period but did 
not persist during 2006–2008.
These results have potentially important implications for valuation and capital budgeting 
of pharmaceutical, biotechnology, and device firms. They raise the possibility of obtaining 
better estimates of a firm's cost of equity using on the cross-sectional relationship 
between risk and R&D intensity. They also suggest the possible value, in practice, of 
comparing values of projects based on estimates of the cost of capital using the CAPM 
and F-F models, at least for small firms. The cost of equity capital will usually be higher 
11
(p. 98) 
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on average for smaller publicly-traded firms and for privately held firms than for the 
samples analyzed in this study due higher R&D intensity and illiquidity.
Along with theory and prior work, this study's results concerning risk and R&D intensity 
also highlight the question of whether a time-varying discount rate should be used to 
value molecules or devices in different stages of development. Although technical 
(scientific) risk is likely diversifiable by investors, early-stage projects have greater R&D 
intensity and thus greater systematic risk. The return required by investors is therefore 
likely to be greater than for late-stage projects. If a constant discount rate is used to 
value all expected future cash flows based on a firm's overall cost of capital, early-stage 
projects will tend to be overvalued and late-stage projects will tend to be undervalued. 
Additional work is needed to determine whether and how time-varying discount rates 
could be employed in practice.
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Notes:
(1.) Also see Cockburn and Lerner (2009), which discusses and cites high betas for early-
stage ventures. A variety of studies have used the CAPM or F-F-based models in event 
studies of abnormal returns for pharmaceutical and biotechnology stocks (see, e.g., 
Bastin and Hubner 2006; Golec et al. 2005; McNamara and Baden-Fuller 2007).
(2.) Also see Ellison and Mullin (2001). In related research, studies of the relationship 
between R&D intensity and equity values have considered whether stock prices 
accurately reflect intangible assets associated with R&D. Chan et al. (2001), for example, 
analyzed the relation between historical stock returns and firms' R&D. Eberhart et al. 
(2004) provided evidence of positive abnormal stock returns for firms with unexpected 
increases in R&D. Lev and Sougiannis (1999) considered a possible relationship between 
R&D and the book-to-market phenomenon in stock returns. Other studies have 
considered possible valuation effects of the accounting treatment of R&D. See, for 
example, Sougiannis et al. (2005); specific applications to the pharmaceutical and 
biotechnology sectors include Joos (2002), an empirical analysis of relations between 
pharmaceutical firms' book-to-market ratios and R&D; Healy et al. (2002), a simulation 
analysis of relations between accounting treatment of R&D and a pharmaceutical firm's 
economic value; Hand (2004), an empirical analysis of the relation between market equity 
value and R&D measures in biotechnology; and Clem et al. (2004), an examination of 
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stock price reactions to proposed changes in accounting treatment of purchased in-
process R&D for R&D-intensive firms.
(3.) See, for example, Cochrane (2001), Chapter 5.
(4.) The minimum market capitalization criterion was designed to reduce issues 
associated with infrequent trading. A handful of firms that met the other criteria were 
excluded on this basis.
(5.) Clinical research organizations and laboratories were excluded even if they reported 
some R&D expense.
(6.) Classifying size groups based on the F-F size portfolio cutoffs would have produced 
too few small firms for meaningful analysis.
(7.) For regressions of betas on the ratio of R&D to sales, qualitatively similar results 
were obtained using the raw values of the variable.
(8.) The dearth of debt financing likely reflects a variety of influences, including (1) large 
amounts of intangible assets that might be threatened by financial instability, (2) lower 
marginal value of debt tax shields in the presence of tax shields arising from the 
immediate tax deductibility of R&D expenditures, and (3) historically large generation of 
internal funds, which reduces the need for external financing. See Passov (2003) for 
further discussion.
(9.) The estimated alpha from equation (4), sometimes called “Jensen's alpha,” is a 
common measure of risk-adjusted performance for portfolios and individual securities.
(10.) Myers and Shyam-Sunder (1996) employed a projected 20-year Treasury rate less 
the average term premium compared with Treasury bills to serve as a proxy for the 
riskless rate for long-duration R&D investments.
(11.) Although higher CAPM betas for device companies than for pharmaceutical firms 
during 2006-2008 could reflect greater price elasticity of demand for devices, it is not 
clear why greater price elasticity would lead to higher book-to-market betas in the F-F 
framework.
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